| To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC). (NCT05236218) | King's College London | 2022-07-20 |
| A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (NCT04813107) | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 2021-12-28 |
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (NCT04960709) | AstraZeneca | 2021-08-05 |
| Multi-parametric MRI in Patients of Bladder Cancer (NCT06362330) | The First Affiliated Hospital with Nanjing Medical University | 2021-07-01 |
| A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy (NCT04660344) | Hoffmann-La Roche | 2021-05-03 |
| Gender-related Characteristics of Bladder Cancer Treatment (NCT04687254) | University of Florence | 2020-09-01 |
| A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer (NCT04209114) | Bristol-Myers Squibb | 2020-02-05 |
| A Novel Pathway to Detect Muscle-invasive Bladder Cancer Based on Integrated Clinical Features and VI-RADS Score on MRI (NCT06807008) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2020-01-01 |
| Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma (NCT04099589) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-10-01 |
| Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer (NCT04101812) | Tianjin Medical University Second Hospital | 2019-09-17 |
| Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study (NCT03832673) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2019-05-22 |
| Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma (NCT04047693) | Pusan National University Yangsan Hospital | 2019-05-01 |
| A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) (NCT03773666) | Dana-Farber Cancer Institute | 2019-02-20 |
| Avelumab and Radiation in Muscle-Invasive Bladder Cancer (NCT03747419) | Dana-Farber Cancer Institute | 2018-12-13 |
| Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NCT03732677) | AstraZeneca | 2018-11-16 |
| A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer (NCT03661320) | Bristol-Myers Squibb | 2018-11-06 |
| Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin (NCT03234153) | Insel Gruppe AG, University Hospital Bern | 2018-07-15 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (NCT03397394) | pharmaand GmbH | 2018-06-01 |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy (NCT03294304) | Masonic Cancer Center, University of Minnesota | 2018-01-29 |
| Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer (NCT04053101) | Institut Bergonié | 2017-04-01 |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (NCT02546661) | AstraZeneca | 2016-12-28 |
| Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging (NCT02462239) | Ontario Clinical Oncology Group (OCOG) | 2016-05-06 |
| Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer (NCT02716896) | The University of Texas Health Science Center at San Antonio | 2016-05-01 |
| Basal Like Bladder Cancer : Signature and Therapeutic (NCT02648100) | Assistance Publique - Hôpitaux de Paris | 2014-03-01 |
| Dose Dense MVAC for Muscle Invasive Bladder Cancer (NCT01031420) | Fox Chase Cancer Center | 2009-12-07 |